# A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

> **NCT06397027** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 22 (estimated)

## Conditions studied

- Refractory Acute Leukemia
- Pediatric Relapsed

## Interventions

- **DRUG:** Ziftomenib
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT06397027
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-27
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06397027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06397027, "A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06397027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*